Cytokine Signatures: Identifying the Proteomic Markers of Acute vs. Persistent Lyme

Overview

The immunological landscape of Lyme borreliosis is not a static monolith but a fluid, proteomic progression governed by the complex interplay between the spirochaete *Borrelia burgdorferi* sensu lato and the human host’s innate and adaptive systems. At INNERSTANDIN, we dissect the molecular architecture of this disease, moving beyond the reductive 'positive/negative' serology to identify the precise cytokine signatures that differentiate acute infection from the controversial and often debilitating state of persistent Lyme. The challenge in modern clinical diagnostics remains the significant disparity between the pathogen’s ability to sequester in low-oxygen, collagen-rich niches and the peripheral blood’s proteomic reflection of that presence. Understanding these signatures is fundamental to resolving the diagnostic stalemate that leaves thousands of UK patients in a state of physiological flux.

In the acute phase, typically within days of haematogenous dissemination, the host immune system orchestrates a pro-inflammatory burst characterised by a Th1-skewed cytokine profile. Research indexed in *The Lancet Infectious Diseases* and various PubMed-validated cohorts indicates a marked elevation in interferon-gamma (IFN-γ) and its induced chemoattractants, specifically CXCL9 and CXCL10. This 'interferon signature' is a hallmark of the early systemic response, as Toll-like receptors (TLR2/1) on dendritic cells and macrophages recognise the triacylated lipopeptides of the *Borrelia* outer surface proteins (Osps). This stage is high-velocity and metabolically taxing, often manifesting clinically as the erythema migrans rash, though the absence of a lesion does not preclude the underlying cytokine storm.

However, as the infection transitions from acute to persistent, the proteomic narrative shifts toward a state of immunological exhaustion or dysregulation. Persistent Lyme—frequently categorised under the clinical umbrella of Post-Treatment Lyme Disease Syndrome (PTLDS)—is marked by a distinct lack of immune resolution. Here, we observe a paradoxical elevation of IL-6 and IL-17, suggesting a chronic activation of the Th17 pathway, coupled with a failure of the regulatory T-cell (Treg) response to suppress systemic inflammation. Peer-reviewed data suggests that individuals with persistent symptoms exhibit elevated levels of CCL19, a chemokine involved in lymphoid tissue homing, which remains high long after standard antibiotic protocols have ceased. This suggests a 'molecular scar' or a continued cryptic antigenic stimulus that the current NHS diagnostic framework, heavily reliant on outdated ELISA and Western Blot methodologies, fails to capture.

The systemic impact of these fluctuating cytokine signatures extends to the blood-brain barrier and the central nervous system. The persistent elevation of pro-inflammatory cytokines such as TNF-α and IL-1β facilitates neuroinflammation, providing a biological basis for the 'brain fog' and cognitive dysfunction reported by patients. At INNERSTANDIN, we assert that the truth of Lyme disease lies in these proteomic markers; they provide an objective lens through which to view the host’s failed attempt at spirochaetal clearance and the subsequent chronic inflammatory cascade. By identifying these specific cytokine signatures, we move closer to a precision-medicine approach that acknowledges the biological reality of persistent Lyme beyond the limitations of contemporary microbial culture.

The Biology — How It Works

The pathogenesis of *Borrelia burgdorferi* infection is not merely a battle of attrition between pathogen and host; it is an orchestrated reconfiguration of the human immunome. At the heart of this transition from acute infection to persistent morbidity lies the evolution of the cytokine signature—a proteomic footprint that defines the clinical trajectory of the patient. Understanding this transition is central to the mission at INNERSTANDIN, where we peel back the layers of conventional diagnostic myopia to reveal the molecular reality of Lyme disease.

In the acute phase, the innate immune response is characterised by a robust, albeit often insufficient, Th1-mediated pro-inflammatory surge. Upon the inoculation of *Borrelia* spirochaetes via an *Ixodes* tick bite, the host’s Toll-like receptors (primarily TLR2) recognise the pathogen’s surface lipoproteins, such as OspC. This trigger initiates the secretion of interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ). Research published in *The Journal of Clinical Investigation* and corroborated by UK-based longitudinal studies highlights the diagnostic potency of CXCL13—a B-cell-attracting chemokine. In the acute stages of Lyme neuroborreliosis, CXCL13 levels in the cerebrospinal fluid skyrocket, serving as a highly sensitive marker of early central nervous system involvement, often preceding the development of detectable antibodies.

However, the biology of persistence is marked by a profound shift in this proteomic landscape. When the infection evades initial clearance—facilitated by the spirochaete’s ability to undergo antigenic variation (via the VlsE recombination site) and sequester in bradytrophic tissues like collagen and cartilage—the cytokine profile transitions from a Th1 dominance to a more complex, dysregulated Th17/Treg axis. Evidence-led research, including proteomic assays published in *PLOS Pathogens*, identifies elevated levels of CCL19 as a hallmark of persistent Lyme. CCL19, a chemokine involved in homeostatic lymphoid trafficking, remains pathologically elevated in individuals who remain symptomatic post-antibiotic treatment (often termed PTLDS), suggesting a state of chronic immune activation or the presence of persistent antigenic debris.

This persistent signature is not merely a 'lingering' response but a fundamental breakdown in immune resolution. The systemic impact is profound: chronic elevations in IL-23 and IL-17 drive a pro-inflammatory loop that targets the synovial membranes and the blood-brain barrier, leading to the hallmark arthritic and cognitive 'fog' associated with the disease. In the UK context, where *Borrelia garinii* and *Borrelia afzelii* are more prevalent than the North American *burgdorferi* sensu stricto, these signatures may manifest with even greater neurological bias. INNERSTANDIN recognises that the failure to differentiate between an acute inflammatory 'storm' and a persistent 'smoulder' is why many patients remain trapped in a cycle of inadequate treatment. The biology reveals that persistent Lyme is as much a proteomic disorder as it is an infectious one, necessitating a shift toward cytokine-targeted diagnostics and precision immunomodulation.

Mechanisms at the Cellular Level

The initial cellular encounter between the *Borrelia burgdorferi* sensu lato complex and the human innate immune system is governed by the recognition of triacylated lipopeptides, such as Outer Surface Protein A (OspA), by Toll-like receptor 2 (TLR2) and TLR1 heterodimers on the surface of resident macrophages and monocyte-derived dendritic cells. In the United Kingdom, where *Borrelia garinii* and *Borrelia afzelii* are more prevalent than the North American *B. burgdorferi* sensu stricto, this interaction initiates a robust intracellular signalling cascade via the MyD88-dependent pathway. This culminates in the nuclear translocation of NF-κB and the subsequent secretion of a specific acute-phase proteomic signature: Interleukin-6 (IL-6), Tumour Necrosis Factor-alpha (TNF-α), and Interleukin-12 (IL-12). This Th1-polarized response is essential for early spirochaetal containment. However, the true proteomic hallmark of acute Lyme, as identified in peer-reviewed literature including *The Lancet Infectious Diseases*, is the rapid elevation of CXCL13. This B-cell chemoattractant serves as a definitive marker for active spirochaetal dissemination, reflecting the host's attempt to organise tertiary lymphoid structures within peripheral tissues and the central nervous system.

As the infection transitions from the acute phase to a state of persistence, the cellular mechanism shifts from overt inflammatory clearance to complex immune evasion and homeostatic dysregulation. *Borrelia* exhibits profound tissue tropism, sequestering within the extracellular matrix (ECM) and fibroblast niches, where it is shielded from circulating leucocytes. Crucially, the spirochaete employs the VlsE (Variable major protein-like sequence, expressed) recombination system, which continually alters surface lipoproteins to evade humoral recognition. At the INNERSTANDIN research level, we identify that this persistent phase is characterised by a 'cytokine decoupling.' While acute signatures are defined by IFN-γ and IL-12, persistent Lyme often manifests a Th17-driven milieu, marked by elevated IL-17 and IL-23, which drives chronic, non-resolving tissue inflammation.

Furthermore, the persistent proteomic profile is defined by the upregulation of Matrix Metalloproteinases, specifically MMP-9. This enzyme facilitates the degradation of the vascular basement membrane, promoting blood-brain barrier permeability and the infiltration of inflammatory mediators into the neurovasculature. Unlike the transient nature of CXCL13 in acute cases, persistent states are often associated with sustained elevations of CCL19, a chemokine involved in T-cell and dendritic cell trafficking. This indicates a state of 'antigenic frustration,' where the immune system remains in a perpetual state of recruitment without achieving pathogen clearance. This chronic signalling leads to mitochondrial oxidative stress within host cells, as evidenced by increased reactive oxygen species (ROS) and the depletion of intracellular glutathione. This cellular exhaustion explains the systemic fatigue and multi-organ morbidity observed in persistent cases, distinguishing it mechanistically from the self-limiting inflammation of an initial infection. By identifying these divergent proteomic markers, INNERSTANDIN aims to expose the biological reality of persistent borreliosis, moving beyond the reductive 'post-infectious' narratives often found in standard clinical frameworks.

Environmental Threats and Biological Disruptors

The transition from a localised *Borrelia burgdorferi* infection to a disseminated, persistent systemic pathology is not merely a failure of antibiotic clearance; it is a profound collapse of host homeostasis orchestrated by a convergence of environmental disruptors and pathological proteomic shifts. At INNERSTANDIN, we recognise that the biological terrain of the UK patient—often saturated with anthropogenic pollutants and sub-clinical co-infections—dictates the cytokine signature that emerges post-inoculation. In the acute phase, the proteomic architecture is typically defined by a robust, albeit often insufficient, Th1-mediated response. Peer-reviewed data (Aucott et al., *The Lancet Infectious Diseases*) highlight the initial elevation of interferon-gamma (IFN-γ) and pro-inflammatory chemokines such as CXCL9 and CXCL10. However, in cases of persistent Lyme, this signature undergoes a maladaptive metamorphosis, often driven by external biological disruptors that compromise the blood-brain barrier and the gut-immune axis.

Environmental threats, including mycotoxins from water-damaged buildings and heavy metal accumulation (specifically lead and mercury, prevalent in UK industrial legacy areas), act as "second hits" to the immune system. These toxicants interfere with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling pathway, potentially locking the individual into a state of chronic cytokine dysregulation. When *Borrelia* spirochaetes encounter a host burdened by these environmental stressors, the proteomic marker CCL19 often remains pathologically elevated long after the initial infection. Research published in *Clinical Infectious Diseases* suggests that persistent CCL19 levels serve as a primary biomarker for Post-Treatment Lyme Disease Syndrome (PTLDS), indicating continued immune activation within secondary lymphoid organs. This is not a "phantom" illness; it is a measurable proteomic reality where the host’s biological landscape has been terraformed by the pathogen and its environmental accomplices.

Furthermore, the presence of co-infections such as *Babesia* or *Bartonella*—frequently overlooked in standard UK primary care settings—functions as a biological disruptor that skews the cytokine profile away from resolution. These co-pathogens induce a Th17-dominant response, characterised by high levels of IL-17 and IL-23, which are associated with autoimmune-like neuroinflammation and joint degradation. The synergy between *Borrelia* and these environmental co-factors facilitates the formation of biofilm matrices, shielding the bacteria from both leucocytes and pharmacological intervention. At INNERSTANDIN, we expose the inadequacy of the current two-tier testing paradigm, which ignores these proteomic nuances. To truly map the pathomechanism of persistent Lyme, one must look beyond the antibody and scrutinise the persistent cytokine storm (IL-6, TNF-α, and IL-8) that signifies a system unable to return to equilibrium due to the persistent "noise" of environmental and biological disruptors. This systemic failure represents a total hijacking of the host’s immunometabolic pathways, necessitating a radical shift in how we identify and treat the complex proteomic signatures of the modern Lyme patient.

The Cascade: From Exposure to Disease

The pathogenesis of Lyme borreliosis, initiated by the haematogenous dissemination of the *Borrelia burgdorferi* sensu lato complex, represents a masterclass in immunological evasion and cytokine dysregulation. In the United Kingdom, where *Ixodes ricinus* serves as the primary vector, the transition from local cutaneous inoculation to systemic involvement is governed by a sophisticated proteomic dialogue between the spirochaete and the host’s innate immune sensors. Upon entry, *Borrelia* exploits tick salivary proteins, such as Salp15, which specifically inhibits dendritic cell activation and interferes with T-cell receptor signalling. This initial "silent phase" masks the pathogen, allowing for the establishment of a niche before the overt inflammatory cascade begins. INNERSTANDIN analysis reveals that the initial acute response is typically characterised by a Th1-dominant cytokine profile, driven by the activation of Toll-like receptors (TLRs), specifically TLR2/1 heterodimers, which recognise the outer surface lipoproteins (Osps) of the spirochaete.

As the spirochaetes disseminate, the proteomic signature shifts. Acute Lyme disease is marked by a robust elevation of Interferon-gamma (IFN-γ) and chemoattractants such as CXCL9 and CXCL10. These markers are indicative of a vigorous attempt by the host to recruit macrophages and natural killer cells to the sites of infection. Research published in *The Lancet Infectious Diseases* suggests that while this pro-inflammatory surge is essential for bacterial clearance, its persistence—or failure to resolve—lays the groundwork for chronic sequelae. The "cascade" becomes a pathological loop; if the initial Th1 response fails to eradicate the pathogen due to *Borrelia’s* high rate of antigenic variation via VlsE recombination, the host may transition into a state of chronic immune activation or "smouldering" inflammation.

The distinction between acute and persistent Lyme is most clearly evidenced in the divergent proteomic profiles of IL-17A and CXCL13. In cases of persistent Lyme, or Post-Treatment Lyme Disease Syndrome (PTLDS), the cytokine signature often deviates from the classical Th1 pathway toward a Th17-mediated response. Elevated levels of IL-23 and IL-17 have been identified in patients with refractory Lyme arthritis and persistent neurological symptoms, suggesting a shift toward auto-inflammatory pathology. Furthermore, CXCL13 serves as a critical biological marker; in the UK context, where *Borrelia garinii* is prevalent, this B-cell chemoattractant in the cerebrospinal fluid is a hallmark of early neuroborreliosis. However, in persistent cases, the continued elevation of systemic IL-6 and TNF-α, coupled with a paradoxical rise in the anti-inflammatory cytokine IL-10, indicates a state of immune exhaustion and cytokine "chaos." At INNERSTANDIN, we recognise that these persistent markers are not merely remnants of a past infection but are evidence of a sustained biological battle, where the spirochaete’s ability to sequester in collagen-rich tissues or form biofilm-like aggregates continues to provoke a dysregulated, multi-systemic proteomic storm. This cascade, from the initial tick bite to the complex cytokine signatures of chronic disease, highlights the inadequacy of standard two-tier serology, which fails to capture the kinetic reality of the host’s proteomic response.

What the Mainstream Narrative Omits

The prevailing clinical orthodoxy in the United Kingdom, largely dictated by the National Institute for Health and Care Excellence (NICE) guidelines, remains tethered to an antiquated, binary understanding of *Borrelia burgdorferi* infection. This reductionist framework posits that once the spirochaetal load is theoretically neutralised by short-course tetracyclines, the biological narrative concludes. However, at INNERSTANDIN, we recognise that this 'convalescent' period often masks a complex, proteomic sub-stratum of persistent immune activation that traditional two-tier serology—relying on the inherently flawed ELISA and Western Blot assays—is fundamentally unequipped to detect. The mainstream narrative omits the critical transition from an acute Th1-mediated pro-inflammatory response to a chronic, dysregulated state characterised by specific 'cytokine fingerprints' that persist long after the pathogen has ostensibly been cleared.

Research published in *The Lancet Infectious Diseases* and *Frontiers in Immunology* highlights that persistent Lyme symptomatology is not a psychosomatic phenomenon but is driven by a distinct proteomic signature. In acute cases, the secretome is dominated by high concentrations of Interferon-gamma (IFN-γ) and Interleukin-23 (IL-23), driving a Th17-heavy response designed to sequester the spirochaetes. Conversely, in individuals suffering from persistent symptoms (often dismissively labelled as Post-Treatment Lyme Disease Syndrome, or PTLDS), there is a significant elevation of the chemokine CCL19 (MIP-3-beta). Studies by Aucott et al. have demonstrated that elevated CCL19 levels persist for months post-treatment in patients with lingering morbidity, suggesting a failure of the immune system to return to homeostasis. This 'chemokine tail' indicates ongoing T-cell recruitment to sites of sequestered inflammation, likely within the central nervous system or synovial tissues, where *Borrelia* may persist in biofilm forms or L-form variants.

Furthermore, the mainstream failure to acknowledge the role of CXCL13 as a definitive marker for neuroborreliosis represents a significant diagnostic gap. While the UK medical establishment focuses on late-stage IgG expansion, the proteomic reality involves a complex interplay of Interleukin-6 (IL-6) and Interleukin-8 (IL-8), which facilitate the breakdown of the blood-brain barrier. At INNERSTANDIN, we scrutinise the evidence regarding the 'interferon signature'—a sustained elevation of Type I IFN-regulated genes—which serves as a molecular harbinger of chronic autoimmunity triggered by molecular mimicry. The omission of these proteomic markers from standard diagnostic pathways ensures that the transition from acute infection to a persistent, systemic inflammatory state remains 'invisible' to the NHS, leaving patients in a biological limbo that the current medical paradigm refuses to map. This is not merely an absence of evidence, but a refusal to utilise the proteomic tools already validated in peer-reviewed literature to identify the smouldering cytokine fire of persistent Lyme.

The UK Context

The epidemiological landscape of Lyme borreliosis within the United Kingdom presents a distinct proteomic challenge, primarily due to the dominance of *Borrelia garinii* and *Borrelia afzelii*—genospecies that exhibit markedly different cytokine induction patterns compared to the North American *Borrelia burgdorferi sensu stricto*. At INNERSTANDIN, we recognise that the UK’s clinical reliance on standard two-tier serology often fails to capture the nuanced cytokine shifts that define the transition from acute erythema migrans to disseminated, persistent pathology. Peer-reviewed data, including longitudinal studies published in *The Lancet Infectious Diseases*, suggest that the UK cohort often exhibits a ‘proteomic shadow’ where traditional antibody responses lag, yet pro-inflammatory signatures remain aggressively upregulated.

In the acute UK context, the initial innate immune response is characterised by a rapid elevation of CXCL13, particularly in cases of early neuroborreliosis—a manifestation more prevalent with European strains. This chemokine serves as a critical biomarker for B-cell recruitment within the cerebrospinal fluid. However, the systemic failure to resolve this inflammation leads to a Th1/Th17 skew. Research into UK-specific cohorts indicates that persistent sufferers often demonstrate sustained elevations of Interleukin-23 (IL-23) and IL-17A, creating a self-perpetuating inflammatory loop that damages the blood-brain barrier and peripheral nerve fibres. This is not merely "post-treatment fatigue" but a measurable state of proteomic dysregulation.

Furthermore, the UK’s NICE (National Institute for Health and Care Excellence) guidelines have historically overlooked the significance of the CCL19 chemokine, which research suggests remains elevated in patients who fail to recover following standard antibiotic protocols. This persistent cytokine elevation acts as a molecular fingerprint of ongoing immune activation, likely driven by sequestered spirochaetal antigens or molecular mimicry involving host proteins like HLA-DRB1. At INNERSTANDIN, we expose the biological reality: the British clinical framework must shift from binary ‘infected/cured’ paradigms toward high-sensitivity proteomic profiling. The systemic impact of these signatures involves chronic mitochondrial oxidative stress and neuro-inflammation, which are frequently misdiagnosed within the NHS as fibromyalgia or chronic fatigue syndrome, despite clear evidence of a persistent Borrelia-driven cytokine storm. Only by mapping these proteomic markers can we move beyond symptomatic management into targeted, mechanism-based biological interventions.

Protective Measures and Recovery Protocols

The mitigation of persistent Lyme disease phenotypes requires a paradigm shift from simple pathogen eradication to the sophisticated modulation of the host’s proteomic environment. At INNERSTANDIN, we recognise that the transition from an acute *Borrelia burgdorferi* infection to a chronic, systemic inflammatory state is governed by a failure to resolve the initial cytokine surge, leading to a state of "molecular scarring." Recovery protocols must therefore be bifurcated: first, targeting the immediate hyper-inflammatory response of the acute phase, and second, addressing the indolent, Th17-dominant cytokine signatures that characterise Persistent Lyme Disease Syndrome (PLDS).

During the acute phase, the primary objective is the suppression of the NF-κB signalling pathway to prevent the overproduction of IL-6, TNF-α, and IL-8. Research published in *The Lancet Infectious Diseases* suggests that while standard UK NICE-recommended antibiotic protocols (such as doxycycline) effectively reduce spirochaetal load, they often fail to address the residual pro-inflammatory markers that predict long-term morbidity. To counter this, adjunctive protocols should focus on Nrf2 activation. Compounds such as Sulforaphane and high-dose Liposomal Glutathione serve to upregulate endogenous antioxidant defences, thereby protecting the vascular endothelium from the oxidative stress induced by the spirochaetal lipopolysaccharide-like surface proteins (VlsE).

In the context of persistent illness, the proteomic signature shifts toward elevated CCL19—a chemokine associated with the formation of tertiary lymphoid structures and persistent T-cell activation. Evidence-led recovery requires the implementation of biological agents that can cross the blood-brain barrier to modulate neuroinflammation. For instance, the use of polyphenolic compounds such as Luteolin and Baicalin has shown significant efficacy in inhibiting the release of IL-1β from microglial cells. These substances act as selective immunomodulators, shifting the immune system away from a maladaptive Th17 response and toward a regulatory T-cell (Treg) dominance, which is essential for tissue repair and the resolution of "brain fog" and autonomic dysfunction.

Furthermore, systemic recovery must address the dysregulation of the HPA axis and the subsequent cortisol resistance that often accompanies prolonged cytokine elevation. Advanced protocols include the use of adaptogenic molecular chaperones and the optimisation of mitochondrial bioenergetics. By utilising Coenzyme Q10 in the ubiquinol form and PQQ (Pyrroloquinoline quinone), clinicians can support the mitoprotective mechanisms necessary to overcome the cellular fatigue driven by IFN-γ-induced metabolic arrest. At INNERSTANDIN, we posit that true recovery is only achievable when the proteomic "noise" of persistent CXCL13 and CCL19 expression is silenced through a multi-modal approach that integrates precise antimicrobial intervention with rigorous host-optimisation strategies. This truth-exposing perspective reveals that the pathogen is merely the trigger; the enduring biological damage is a result of a proteomic system that has lost its homeostatic compass. Only by recalibrating these cytokine signatures can the patient transition from a state of chronic immune exhaustion to profound biological resilience.

Summary: Key Takeaways

The proteomic distinction between acute *Borrelia burgdorferi* infection and persistent Lyme disease—often clinically categorised as Post-Treatment Lyme Disease Syndrome (PTLDS)—is defined by a fundamental shift from a robust, pro-inflammatory Th1-mediated response to a chronic state of immunological dysregulation and exhaustion. In the acute phase, longitudinal data published in *The Lancet Infectious Diseases* and *Nature Communications* highlight a dominant IFN-γ-driven signature, characterised by elevated titres of CXCL9 and CXCL10. These markers reflect a systemic attempt by the innate and adaptive systems to sequester the spirochaetal load. Conversely, INNERSTANDIN identifies that persistent phenotypes are frequently marked by sustained elevations in CCL19, a chemokine essential for T-cell trafficking to secondary lymphoid tissues, suggesting an entrenched immune activation that survives standard antibiotic protocols.

Furthermore, the transition to a Th17-dominant profile, coupled with elevations in IL-6, TNF-α, and TGF-β, facilitates the systemic multi-organ pathology observed in UK clinical cohorts, particularly regarding neuroborreliosis and musculoskeletal degradation. This molecular persistence, often exacerbated by spirochaetal evasion into immune-privileged niches, underscores the inadequacy of relying solely on antiquated two-tier serology. The evidence-led truth reveals that identifying these specific cytokine signatures is paramount for differentiating between active inflammatory resolution and the lingering proteomic debris that drives chronic symptomatology. At INNERSTANDIN, we recognise that the biological reality of Lyme disease lies in these high-density cytokine profiles, which provide a more accurate diagnostic map than traditional morphological or antibody-centric tests.